Lawrence Klein

Lawrence Klein is currently serving as the Chief Executive Officer at Oruka Therapeutics since February 2024. Prior to this role, they held positions at Versant Ventures as a Partner, Jasper Therapeutics as a Board Member, Dyne Therapeutics as a Board Member, and CRISPR Therapeutics as the Chief Operating Officer & Chief Business Officer. Lawrence obtained a PhD in Biophysics from Stanford University and a BS in Biochemistry and Physics from the University of Wisconsin-Madison.